AMAG Announces Positive Topline Data From Phase 3 Feraheme® (ferumoxytol) Label Expansion Study
May 02, 2017 11:02 am UTC| Business
Achieved all primary and secondary safety and efficacy endpoints On track to file sNDA mid-year with a potential approval and launch in first half of 2018 Company to discuss clinical data on first quarter earnings call...
AMAG Announces Positive Topline Data From Phase 3 Feraheme® (ferumoxytol) Label Expansion Study
May 02, 2017 11:02 am UTC| Business
Achieved all primary and secondary safety and efficacy endpoints On track to file sNDA mid-year with a potential approval and launch in first half of 2018 Company to discuss clinical data on first quarter earnings call...
AMAG Announces Positive Topline Data From Phase 3 Feraheme® (ferumoxytol) Label Expansion Study
May 02, 2017 11:02 am UTC| Business
Achieved all primary and secondary safety and efficacy endpoints On track to file sNDA mid-year with a potential approval and launch in first half of 2018 Company to discuss clinical data on first quarter earnings call...
Oxford Immunotec Reports First Quarter 2017 Financial Results
May 02, 2017 11:02 am UTC| Business
First quarter revenue of $21.5 million, an increase of 26% compared to prior year periodFirst quarter Tuberculosis revenue of $18.5 million, an increase of 8% compared to prior year periodFirst quarter Tick-borne disease...
Oxford Immunotec Reports First Quarter 2017 Financial Results
May 02, 2017 11:02 am UTC| Business
First quarter revenue of $21.5 million, an increase of 26% compared to prior year periodFirst quarter Tuberculosis revenue of $18.5 million, an increase of 8% compared to prior year periodFirst quarter Tick-borne disease...
Oxford Immunotec Reports First Quarter 2017 Financial Results
May 02, 2017 11:02 am UTC| Business
First quarter revenue of $21.5 million, an increase of 26% compared to prior year periodFirst quarter Tuberculosis revenue of $18.5 million, an increase of 8% compared to prior year periodFirst quarter Tick-borne disease...
May 02, 2017 11:01 am UTC| Business
EWING, N.J., May 02, 2017 -- Antares Pharma, Inc. (NASDAQ:ATRS) today announced it will release its first quarter 2017 financial results and recent operating progress before the market opens on Tuesday, May 9, 2017....
Trump Floats Greenland Framework, Bets Big on ‘Mission 500’ With India